The global anxiety disorders and depression treatment market is estimated to reach US$ 18 Billion in 2021, growing at a CAGR of 0.9% from 2017 to 2021.
Anxiety disorders and depression are different, but people with depression often experience symptoms similar to those of an anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. Depression is a mood disorder with a multitude of symptoms, including lowered mood, fatigue and disturbed sleep, anhedonia, low self-esteem and self-confidence, loss of appetite, and a low libido. Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States. Depression is one of the most common mental disorders in the United States, affecting approximately 6.7% of adults each year, according to the Anxiety and Depression Association of America (ADAA). The most common type is major depressive disorder (MDD), with dysthymia and bipolar disorder also being distinct depressive disorders. But each disorder has its own causes and its own emotional and behavioral symptoms. Anxiety disorders and depression are common psychiatric disorders that affect a large number of people during their lifetime. According to the WHO, by 2020, depression and anxiety disorders including stress related psychiatric conditions would rival cardiovascular diseases as the major health disorder with the highest disease burden. Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States and worldwide. Currently, medications together with psychotherapy are the best treatment approach for patients suffering from depression and anxiety disorders.
Current treatments include antidepressants which may not cure depression, antidepressants can reduce symptoms, such as low mood, anxiety, and decreased energy. The main medications used to treat depression include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, bupropion, mirtazapine, and adjunctive therapies such as atypical antipsychotics. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have reasonable efficacy data in anxiety disorders but are usually reserved for second-line treatment due to safety and tolerability issues. The benzodiazepines play an important role in the treatment of some anxiety disorders, however these agents too are usually reserved for second-line or adjunctive use due to tolerability and abuse liability issues. Serotonin includes Vortioxetine (Lundbeck) and Vilazodone (Merck), Melatonin (Agomelatine), Norepinephrine and Dopamine includes Guanfacine and Nepicastat/Nepicast, while second generation antipsychotics includes Aripiprazole and Brexpiprazole, Glutamate and GABA includes Pregabalin and Ketamine, Glutamate metabotropic receptor modulators, Neuropeptides include Corticotrophin-releasing factor (CRF) or hormone (CRH), Neuropeptide Y (NPY), and Cholecystokinin (CCK). The pipeline drugs are expected to compete for market share initially at the second and third line of therapy, as the first drug prescribed by physicians is typically a generic SSRI antidepressant, in accordance with the major treatment guidelines. New anxiety medications in development include Aloradine (PH94B), B-GOS, IW-2143 (BNC210), S32212, SL-651,498, etc.
Visit Anxiety Disorders and Depression Treatment Market by Drug Class (Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake, Atypical Antipsychotics, Tricyclic Antidepressants, Tetracyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Anticonvulsants) and Forecast 2017-2021. The global anxiety disorders and depression treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global anxiety disorders and depression treatment market report also provides detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global anxiety disorders and depression treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the anxiety disorders and depression treatment market and profiled in this report include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline plc, H. Lundbeck A/S, Pfizer, Inc., Merck & Co., Inc. and Sanofi S.A.
1. Drug Class
1.2. Atypical Antipsychotics
1.5. Monoamine Oxidase Inhibitors
1.6. Selective Serotonin Reuptake Inhibitors
1.7. Serotonin-Norepinephrine Reuptake
1.8. Tetracyclic Antidepressants
1.9. Tricyclic Antidepressants
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AstraZeneca PLC
3.2 Eli Lilly and Company
3.3 Forest Laboratories, Inc.
3.4 GlaxoSmithKline plc
3.5 H. Lundbeck A/S
3.6 Johnson& Johnson
3.7 Merck & Co., Inc.
3.8 Pfizer, Inc.
To request Table of Contents and Sample Pages of this report visit: